Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025
Biomea Fusion, Inc. is back in the spotlight after the company reported long‑term data showing that its experimental diabetes drug icovamenib can deliver durable blood‑sugar control many months after patients stop taking it. The new results, presented at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease in Los Angeles, pushed Biomea Fusion’s stock higher on Friday and have reignited debate over whether this beaten‑down biotech could still be a high‑risk turnaround story. Nasdaq+1
